AR056862A1 - 1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion - Google Patents
1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacionInfo
- Publication number
- AR056862A1 AR056862A1 ARP060101206A ARP060101206A AR056862A1 AR 056862 A1 AR056862 A1 AR 056862A1 AR P060101206 A ARP060101206 A AR P060101206A AR P060101206 A ARP060101206 A AR P060101206A AR 056862 A1 AR056862 A1 AR 056862A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkynyl
- aryl
- cycloalkyl
- heterocyclyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- -1 iodine, hydroxy- Chemical class 0.000 abstract 55
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 17
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 17
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 12
- 229910052731 fluorine Inorganic materials 0.000 abstract 12
- 239000011737 fluorine Substances 0.000 abstract 12
- 125000001072 heteroaryl group Chemical group 0.000 abstract 12
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 11
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 11
- 229910052794 bromium Inorganic materials 0.000 abstract 11
- 229910052801 chlorine Inorganic materials 0.000 abstract 11
- 239000000460 chlorine Substances 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 abstract 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 abstract 1
- 125000005018 aryl alkenyl group Chemical group 0.000 abstract 1
- 125000005418 aryl aryl group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05006939 | 2005-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056862A1 true AR056862A1 (es) | 2007-10-31 |
Family
ID=36545049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101206A AR056862A1 (es) | 2005-03-30 | 2006-03-29 | 1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7713961B2 (https=) |
| EP (1) | EP1866034A1 (https=) |
| JP (1) | JP2008534541A (https=) |
| AR (1) | AR056862A1 (https=) |
| CA (1) | CA2603404A1 (https=) |
| TW (1) | TW200716152A (https=) |
| WO (1) | WO2006103038A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008534541A (ja) * | 2005-03-30 | 2008-08-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換１，２−エチレンジアミン、前記化合物を含む薬物、それらの使用及びそれらの製造方法 |
| EP1913017A1 (en) * | 2005-08-03 | 2008-04-23 | Boehringer Ingelheim International GmbH | Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii |
| US20090042867A1 (en) * | 2005-08-11 | 2009-02-12 | Klaus Fuchs | Compounds for the treatment of alzheimer's disease |
| US20100144681A1 (en) * | 2005-08-11 | 2010-06-10 | Klaus Fuchs | Compounds for the treatment of alzheimer's disease |
| US20100168070A1 (en) * | 2005-08-11 | 2010-07-01 | Niklas Heine | Compounds for the treatment of alzheimer's disease |
| EP1915339A1 (de) * | 2005-08-11 | 2008-04-30 | Boehringer Ingelheim International GmbH | Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung |
| CA2740107A1 (en) | 2008-10-10 | 2010-04-15 | Purdue Research Foundation | Compounds for treatment of alzheimer's disease |
| US8394807B2 (en) | 2008-11-20 | 2013-03-12 | Purdue Research Foundation | Quinazoline inhibitors of BACE 1 and methods of using |
| US8859590B2 (en) | 2008-12-05 | 2014-10-14 | Purdue Research Foundation | Inhibitors of BACE1 and methods for treating Alzheimer's disease |
| WO2011044057A1 (en) * | 2009-10-05 | 2011-04-14 | Comentis, Inc. | Sulfonamido pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof |
| US20140066488A1 (en) * | 2012-08-30 | 2014-03-06 | Purdue Research Foundation | Inhibitors of Memapsin 2 Cleavage for the Treatment of Alzheimer's Disease |
| EP4337202A4 (en) | 2021-06-18 | 2025-04-02 | Aligos Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 |
| EP4448512A4 (en) | 2021-12-16 | 2025-11-19 | Aligos Therapeutics Inc | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ264143A (en) | 1993-08-09 | 1996-11-26 | Lilly Co Eli | Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production |
| US7087399B1 (en) | 1999-05-13 | 2006-08-08 | Scios, Inc. | β-secretase and modulation of β-secretase activity |
| CA2374610A1 (en) | 1999-06-28 | 2001-01-04 | Jordan J. N. Tang | Catalytically active recombinant memapsin and methods of use thereof |
| EP1392315A1 (en) * | 2001-06-08 | 2004-03-03 | Elan Pharmaceuticals, Inc. | Methods of treating alzheimer's disease |
| WO2003032994A2 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
| US6962934B2 (en) * | 2002-01-04 | 2005-11-08 | Elan Pharmaceuticals, Inc. | Substituted amino carboxamides for the treatment of Alzheimer's disease |
| EP1542964A2 (en) * | 2002-09-27 | 2005-06-22 | Elan Pharmaceuticals, Inc. | Compounds for the treatment of alzheimer's disease |
| ATE443043T1 (de) * | 2002-11-12 | 2009-10-15 | Merck & Co Inc | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer |
| US20050090449A1 (en) | 2003-05-13 | 2005-04-28 | Boehringer Ingelheim International Gmbh | Novel statine derivatives for the treatment of Alzheimer's disease |
| JP2007516207A (ja) * | 2003-06-30 | 2007-06-21 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病の治療のためのＮ−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤 |
| WO2005110422A2 (en) | 2004-05-19 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Treatment of diseases associated with altered level of amyloid beta peptides |
| WO2005113582A1 (en) | 2004-05-22 | 2005-12-01 | Boehringer Ingelheim International Gmbh | Substituted ethane-1,2-diamines for the treatment of alzheimer's disease |
| WO2006050862A1 (en) | 2004-11-10 | 2006-05-18 | Boehringer Ingelheim International Gmbh | Statine derivatives for the treatment of alzheimer's disease |
| WO2006050861A2 (en) | 2004-11-10 | 2006-05-18 | Boehringer Ingelheim International Gmbh | Statine derivatives for the treatment of alzheimer's disease |
| JP2008534541A (ja) * | 2005-03-30 | 2008-08-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換１，２−エチレンジアミン、前記化合物を含む薬物、それらの使用及びそれらの製造方法 |
| EP1913017A1 (en) | 2005-08-03 | 2008-04-23 | Boehringer Ingelheim International GmbH | Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii |
| US20090042867A1 (en) | 2005-08-11 | 2009-02-12 | Klaus Fuchs | Compounds for the treatment of alzheimer's disease |
-
2006
- 2006-03-27 JP JP2008503415A patent/JP2008534541A/ja active Pending
- 2006-03-27 CA CA002603404A patent/CA2603404A1/en not_active Abandoned
- 2006-03-27 WO PCT/EP2006/002769 patent/WO2006103038A1/en not_active Ceased
- 2006-03-27 EP EP06723747A patent/EP1866034A1/en not_active Withdrawn
- 2006-03-29 AR ARP060101206A patent/AR056862A1/es not_active Application Discontinuation
- 2006-03-29 TW TW095110860A patent/TW200716152A/zh unknown
- 2006-03-30 US US11/278,059 patent/US7713961B2/en active Active
-
2009
- 2009-07-29 US US12/511,474 patent/US20090325940A1/en not_active Abandoned
-
2010
- 2010-04-13 US US12/759,167 patent/US20100204160A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1866034A1 (en) | 2007-12-19 |
| WO2006103038A1 (en) | 2006-10-05 |
| TW200716152A (en) | 2007-05-01 |
| US20090325940A1 (en) | 2009-12-31 |
| US7713961B2 (en) | 2010-05-11 |
| JP2008534541A (ja) | 2008-08-28 |
| US20060223759A1 (en) | 2006-10-05 |
| CA2603404A1 (en) | 2006-10-05 |
| US20100204160A1 (en) | 2010-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056862A1 (es) | 1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion | |
| UY33961A (es) | Compuestos de bis(fuoroalquil)-1,4-benziodiazepinona | |
| ECSP045476A (es) | Tiazolidinonas, su preparación y su uso como medicamentos | |
| CO6290658A2 (es) | Derivados de azetidina y ciclobutano como inhibidores de jack | |
| UY32978A (es) | Derivados de la cromenona | |
| CO6561821A2 (es) | Compuesto n-(1h-indazol-4-il)imidazol[1.2-a]piridin -3-carboxamida sustituidos como inhibidores de cfms | |
| CO6280401A2 (es) | Agonistas novedosos de los receptores de glucocorticoides | |
| AR067107A1 (es) | Derivados de tiazol[5,4-b]piridin moduladores de sirtuinas | |
| EA201171098A1 (ru) | 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина | |
| PA8604201A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
| MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
| BRPI0515546A (pt) | compostos para inflamação e usos imune-relacionados | |
| DOP2009000258A (es) | Compuestos amino-heterociclicos | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR090712A1 (es) | Agentes para tratar trastornos que implican la modulacion de receptores de rianodina | |
| AR077413A1 (es) | Derivados piridin-4-ilo | |
| CO6321241A2 (es) | Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) | |
| AR056560A1 (es) | Pirrolopiridinonas como moduladores cb1 | |
| SV2006002098A (es) | Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central ref. pc32250a | |
| AR047529A1 (es) | Compuestos de quinolina sustituidos | |
| EA200700909A1 (ru) | Азаиндолкарбоксамиды | |
| PA8779101A1 (es) | "compuestos tricíclicos como inhibidores de metaloproteinasas matriciales" | |
| ATE396970T1 (de) | 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri | |
| CL2011001050A1 (es) | Compuesto 2-metil-1-(fenilsulfonil)-4-(piperazin-1-il)-1h-bencimidazol, que es ligando de 5-hidroxitriptamina-6; su composicion farmaceutica; modulador de la actividad de 5-ht6; su uso en el tratamiento de trastornos del sistema nervioso central, tal como psicosis, ansiedad, depresión, epilepsia, entre otros. | |
| PA8627001A1 (es) | Compuestos para el tratamiento de enfermedades |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |